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ABSTRACT
Anemia is a common finding in cancer patients, most
often as a result of chemotherapy. Management of
anemia requires a comprehensive approach of ap-
propriate diagnosis, exclusion of reversible causes,
use of erythropoiesis-stimulating agents (ESAs), and
iron supplementation. Recently, consensus guide-
lines on the management of chemotherapy-induced
anemia were published in Europe and the United
States. The present review is intended to be a practi-
cal guide for Canadian physicians, based on pub-
lished guidelines, but specifically tailored to the
Canadian environment.
Recommendations for the use of ESAs are present-
ed, including initiation, target hemoglobin, dosing
and adjustments, monitoring, and re-initiation. Is-
sues of safety are also addressed, including throm-
boembolic risk, impact on survival, and tumour
progression. The importance of iron metabolism and
the use of iron supplementation (both oral and
parenteral) is discussed.
KEY WORDS
Canadian recommendations, anemia, cancer, support-
ive care, erythropoiesis-stimulating agent, ESA, che-
motherapy-induced anemia, CIA, iron, safety
1. INTRODUCTION
Anemia is common in cancer 1 and may be the result
of many factors, including chemotherapy, marrow
infiltration, radiation, nutritional deficiencies, and
blood loss. Anemia in cancer adversely affects the
patient by producing fatigue, cognitive impairment,
a need for blood transfusions, and possible disrup-
tion of therapy. It is therefore incumbent on the treat-
ing physician to address anemia in cancer.
Easily reversible causes such as nutritional defi-
ciencies, hypothyroidism, and iron deficiency should
be corrected immediately; however, these causes ac-
count for only a small proportion of anemias in can-
cer patients.
One method of treating anemia (in addition to
transfusion) is the use of an erythropoiesis-stimulat-
ing agent (ESA). The rationale for the use of ESAs in
chemotherapy-induced anemia (CIA) has been two-
fold: to improve the patient’s hemoglobin level and
to reduce the need for transfusions. A multitude of
clinical trials and meta-analyses have validated the
use of ESAs for these two purposes. In addition, the
data have also demonstrated improvements in qual-
ity of life contributing to the indication for the use of
ESAs in Canada 2–6.
The purpose of the present article is to use pub-
lished data and guidelines and consensus opinion
from Canadian physicians to provide recommenda-
tions for the treatment of CIA in Canada. The recom-
mendations provided here focus specifically on the
use of ESAs for CIA.
A medical guideline aims to guide decisions and
criteria in specific areas of health care by examining
and synthesizing the best current evidence. Guide-
lines can have a significant economic impact in health
care and can also provide appropriate access to new
medications. Patients benefit from guidelines by re-
ceiving timely treatment based on supporting evi-
dence and also better information that facilitates
treatment choice. Health care professionals receive
new recommendations based on current clinical evi-
dence, which also supports quality improvement ac-
tivities. As a result of guidelines, health care systems
may improve their efficiency and optimize value for
money.
2. DISCUSSION
2.1 Existing Guidelines
The American Society of Clinical Oncology / Ameri-
can Society of Hematology (ASCO/ASH), the European
Organization for Research and Treatment of Cancer
(EORTC), and the National Comprehensive Cancer
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Network (NCCN) have all published guidelines for the
use of ESAs in patients with cancer 7–9. Variations be-
tween the guidelines can be attributed primarily to
the scientific literature available at the time of guide-
line development 10:
• The 2002 ASCO/ASH guidelines 7 were based on a
U.S. Agency for Healthcare Research and Qual-
ity topic review covering the literature on ESAs
published between January 1985 and October
1999. During that period, epoetin was the only
ESA available.
• In 2004, EORTC published its guidelines for the
use of ESAs in patients with cancer and CIA 8. These
guidelines were rooted in literature published
from 1996 through 2003 and included a review
of epoetin alfa, epoetin beta, and darbepoetin alfa.
In 2006, the guidelines were updated using lit-
erature published through November 2005 11.
• The NCCN guidelines for the management of CIA 9
are the most recent, having been published in
2007. The guidelines are based on a panel re-
view of an updated meta-analysis in the Cochrane
Database of Systemic Reviews on the use of ESAs
in patients with cancer 6.
2.2 Canadian Recommendations
2.2.1 ESA Treatment Goals and Targets
The goals of ESA management of symptomatic ane-
mic patients with malignancy undergoing systemic
chemotherapy are to maximize quality of life and
minimize transfusion requirements while using the
lowest dose of ESA necessary to achieve a target he-
moglobin level.
International guidelines vary slightly in their rec-
ommendations for target hemoglobin level. The ASCO/
ASH and NCCN hemoglobin target is 120 g/L; EORTC
recommends a target range of 120–130 g/L. Product
monographs for epoetin alfa and darbepoetin alfa both
indicate that target hemoglobin should not exceed
120 g/L, with a rate of rise not greater than 10 g/L
over a 2-week period 12,13.
Notably, a hemoglobin target is a designated value
not to be exceeded, rather than a target to be aimed
for. Hemoglobin levels higher than 130 g/L are not
recommended, because randomized clinical trials
have observed an adverse impact on overall survival
at such levels 14.
2.2.2 ESA Dosing and Adjustments
Optimal ESA dosing and titration for both epoetin alfa
and darbepoetin alfa for patients with cancer receiv-
ing systemic chemotherapy have been well estab-
lished through randomized trials.
Initiating ESA Dose In adults, epoetin alfa and
darbepoetin alfa each have two recommended initia-
tion dosing schedules (Table I). Titration graphs il-
lustrate the mean change in hemoglobin concentra-
tion from initiation of epoetin alfa (Figure 1) and
mean hemoglobin concentration levels for darbepo-
etin alfa (Figure 2) using various dosing regi-
mens 15,16.
Initiating Hemoglobin Level The Canadian standard
has been to initiate ESA therapy at a hemoglobin level
below 110 g/L in symptomatic patients. As with rec-
ommendations on hemoglobin targets, recommenda-
tions on ESA initiation vary slightly between published
guidelines (Table II) The guideline from NCCN 9 rec-
ommends consideration of an ESA when the patient’s
hemoglobin level is below 110 g/L. The guideline
from EORTC 8 initially recommended ESAs for either
asymptomatic or symptomatic cancer patients with
hemoglobin levels of 90–110 g/L who are receiving
chemotherapy. In a 2006 update, EORTC refined the
guideline by stating that “ESAs may be considered in
asymptomatic patients with hemoglobin levels below
119 g/L to prevent a further decline according to in-
dividual characteristics” 11. The guideline from ASCO/
ASH 7 recommends ESAs for patients with hemoglobin
levels below 100 g/L who are receiving chemo-
therapy and, if symptomatic, for patients with hemo-
globin levels below 120 g/L.
Some common principles emerge from the vari-
ous guidelines—for example, a consideration of pa-
tient characteristics such as baseline hemoglobin
level, rate of decline of hemoglobin, number of che-
motherapy cycles remaining, and clinical symptoma-
tology when initiating ESA therapy.
It is important to note that initiation of ESAs should
not be delayed. A meta-analysis by Couture et al. 17
showed that early treatment with epoetin alfa could
reduce the number of red blood cell transfusions in
patients receiving chemotherapy. Quirt et al. 18 fur-
ther demonstrated that the initiation of ESAs at a he-
moglobin level below 100 g/L resulted in a higher
risk of blood transfusions. Finally, a systematic re-
view by Lyman and Glaspy 19 found a reduction in
the relative risk of transfusion and hemoglobin below
100 g/L after early intervention (p < 0.0001). Col-
lectively, these findings suggest that optimal benefit
from ESA treatment of CIA may be achieved through
early intervention.
Monitoring Maintenance therapy requires regular
monitoring of hemoglobin levels. For patients who
are responding, treatment can continue as long as that
response is maintained, tolerance is ongoing, and
systemic chemotherapy is continuing (Table III).
Dose De-escalation If the rate of rise or the absolute
level of hemoglobin achieved exceeds given values
on ESA therapy, dose de-escalation should be initi-
ated (Table IV).
Non-response and Dose Escalation Non-response
can be defined as the failure to achieve a hemoglobin
increase of ³10 g/L in 4 weeks with weekly epoetinMANAGEMENT OF ANEMIA IN CANCER
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TABLE I Initiation of erythropoiesis-stimulating agents (ESAs)
Epoetin alfa 12 schedules Darbepoetin alfa 13 schedules
Three times weekly Once weekly Once weekly Every 3 weeks
150 IU/kg subcutaneously 40,000 IU subcutaneously 2.25  mg/kg subcutaneously 500 mg subcutaneously
FIGURE 1 Profile of mean change in hemoglobin (g/dL) from
baseline after initiation of epoetin alfa, for three times weekly and
weekly dosing regimens 15. Used with permission of Springer Berlin.
alfa, or in 6 weeks with once-weekly or every-
3-weeks darbepoetin alfa. Dose escalation of the ESA
should be predicated on evidence of non-response
and ongoing tolerance to treatment (Table V).
Discontinuation Treatment of anemia with an ESA
should be discontinued if response is lost or if acute
drug toxicities arise. Discontinuation of the ESA may
be considered in patients who experience a throm-
botic event. Considerable controversy remains re-
garding the optimal continuation time for an ESA
following completion of chemotherapy. It is reason-
able to continue ESA therapy for a duration beyond
chemotherapy completion equivalent to 1–2 further
cycles of therapy—for example, a further 6 weeks
for an every-3-weeks regimen).
If, in the epoetin alfa 3-times-weekly dosing
schedule, the hemoglobin increase is less than 10 g/L
and the reticulocyte count increase is less than
40,000 cells/mL above baseline after a further 4 weeks
of therapy at 300 IU/kg, response is unlikely, and
treatment should be discontinued. Similarly, for once-
weekly dosing, if a satisfactory response to the in-
creased weekly dose of 60,000 IU has not been
obtained after a further 4 weeks, then the patient is
unlikely to respond, and treatment should be discon-
tinued 12.
Re-initiation Re-initiation of anemia treatment with
an ESA can be recommended if systemic chemotherapy
for malignant disease is again delivered and is accom-
panied by an observed anemia meeting the same
criteria for initiation of ESA as during previous chemo-
therapy cycles. The patient should have no prior his-
tory of adverse events associated with ESA treatment.
It is suggested that the regular criteria for ESA initia-
tion, dose adjustment, and discontinuation be applied
to all subsequent decisions for ESA re-initiation.
2.2.3 Safety of ESAs
Recent data have signalled safety issues involving
the use of ESAs. These concerns—including throm-
boembolic risk, survival, and tumour proliferation—
are reviewed in this subsection.
Thromboembolic Risk An increased risk of throm-
boembolic events is now felt to be a clearly signifi-
cant side effect of ESAs. The recently published
Cochrane meta-analysis 6 included 9353 cancer pa-
tients enrolled in 57 randomized, placebo-controlled
trials conducted from 1985 to 2005 to evaluate epo-
etin alfa, epoetin beta, or darbepoetin alfa. Treatment
with an ESA increased the risk of thromboembolic
events [relative risk: 1.67; 95% confidence interval
(CI): 1.35 to 2.06], with the risk increasing in propor-
tion with target hemoglobin level (Table VI). The cause
of thromboembolic events arising in patients with
malignancy receiving an ESA is complex, arising from
a multitude of risk factors, including chemotherapy
treatment, presence of metastatic disease, immobil-
ity, and the insertion of central venous access devices.
Survival Analysis in Clinical Trials Negative
Survival Four randomized controlled clinical trials of
ESA therapy for patients with malignancy have dem-
FIGURE 2 Mean hemoglobin concentration (g/dL) after initiation
of darbepoetin alfa, for weekly and every-3-week dosing regimens 16.
Used with permission of Oxford University Press.MIKHAEL et al.
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onstrated a negative impact on overall survival 21–23
[Glaspy J, Smith M, Aapro H, et al. Results from a
phase III, randomized, double-blind, placebo-con-
trolled study of darbepoetin alfa (DA) for the treat-
ment of anemia in patients not receiving chemotherapy
or radiotherapy. Presented at the AACR Annual Meet-
ing 2007; April 14–18, 2007; Los Angeles, CA,
U.S.A.].
The Breast Cancer Erythropoietin Survival Trial
(BEST) randomized non-anemic patients with meta-
static breast cancer to epoetin alfa or to placebo with
a goal of achieving hemoglobin levels of 120–
140 g/L 21. Compared with the group receiving pla-
cebo, the group receiving the ESA had a reduced
overall survival rate at 1 year [hazard ratio (HR): 1.35].
This difference became apparent within the first
4 months of therapy initiation and may have been sec-
ondary to a higher incidence of thrombotic cardio-
vascular events.
The ENHANCE trial randomized patients with head-
and-neck cancer to placebo or epoetin beta with a
goal of achieving hemoglobin levels of 145–
150 g/L 22. Patients were not anemic at randomiza-
tion, and they received concomitant radiation therapy
but not chemotherapy. As in the BEST study, a signifi-
cantly decreased survival rate was observed in the
ESA-treated group (HR: 1.39; 95% CI: 1.07 to 1.74).
Patients randomized to placebo survived a median of
928 days as compared with 605 days in the epoetin
beta group (p = 0.09).
TABLE III Monitoring of erythropoiesis-stimulating agents (ESAs)
Epoetin alfa 12 Darbepoetin alfa
Three times weekly and Weekly dosing schedule Every-3-weeks dosing schedule
weekly dosing schedules
Maintenance therapy requires The Canadian standard has been to monitor Hb, Monitor Hb, prior to dosing, at least every
weekly Hb monitoring  prior to dosing, on a weekly basis until the  3 weeks until the target Hb (120 g/L)
 target Hb (120 g/L) is reached, and every   is reached, and regularly thereafter 13
  1–3 weeks thereafter
Hb = hemoglobin.
TABLE II A comparison of guidelines for the use of erythropoiesis-stimulating agents (ESAs) in patients with cancer
Guidelines
ASCO/ASH 7 EORTC 11 NCCN 9
ESA initiation Hb£100 g/L: Symptomatic patients: Symptomatic patients:
ESA recommended Initiate ESA at Hb=90–110 g/L Hb=100–110 g/L:
100 g/L<Hb£120 g/L: based on consider ESA;
use of ESA determined anemia-related symptoms Hb<100 g/L:
by clinical circumstances Asymptomatic patients: strongly consider ESA
ESA may be initiated Asymptomatic patients
at Hb<119 g/L with risk factors:
to prevent further decline consider ESA
Hb target 120 g/L 120–130 g/L 120 g/L (“optimal”)
Titration Titrate to maintain Continue treatment as long as In patients with a response
Hb of 120 g/L Hb£120–130 g/L and (Hb increased by 10 g/L),
or restart when levels fall patients show titrate dose to maintain
to near 100 g/L symptomatic improvement; optimal Hb (120 g/L)
titrate to lowest effective
maintenance dose in patients
reaching target Hb
Dose escalation After 4 weeks, Decision to dose-escalate Increase ESA dose if
consider dose escalation cannot generally no response
for 4–8 weeks in those be recommended after 4–6 weeks
who do not respond and must be individualized (depending on ESA used)
Discontinuation Continuing ESA >6–8 weeks If no symptomatic improvement Discontinue ESA
in the absence of response or Hb rise by 8–10 weeks, if no response
(<10–20 g/L Hb increase) discontinue ESA at 8–12 weeks
is not beneficial
ASCO/ASH = American Society of Clinical Oncology/American Society of Hematology; EORTC = European Organization for Research and
Treatment of Cancer; NCCN = National Comprehensive Cancer Network; Hb = hemoglobin.MANAGEMENT OF ANEMIA IN CANCER
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The EPO-CAN 20 trial was a randomized, placebo-
controlled trial involving anemic patients with non-
small-cell lung cancer who were not on active
chemotherapy 23. Because of evolving safety concerns
regarding  ESA use in patients not receiving chemo-
therapy, an unplanned interim safety analysis was
performed after 70 patients had been randomized.
Median survival rates were higher in the placebo
group (HR: 1.84), resulting in study closure—although
conclusions were unclear because of the high early
mortality rate and the very small sample size.
Amgen’s 20010103 study was a randomized, pla-
cebo-controlled trial of darbepoetin alfa for anemic
patients with cancer but not receiving chemotherapy
[Glaspy J, Smith M, Aapro H, et al. Results from a
phase III, randomized, double-blind, placebo-
controlled study of darbepoetin alfa (DA) for the treat-
ment of anemia in patients not receiving chemo-
therapy or radiotherapy. Presented at the AACR Annual
Meeting 2007; April 14–18, 2007; Los Angeles, CA,
U.S.A.]. The primary end point of transfusion reduc-
tion was not met, and an increase in mortality was
seen in the ESA arm (HR: 1.29). In this preliminary
report, median follow-up was only 4.3 months. As
in the EPO-CAN 20 study, the use of ESAs in patients
not on chemotherapy has not been common practice
and is now discouraged.
Summarizing these four trials, BEST and ENHANCE
treated patients to higher-than-recommended target
hemoglobin levels, and the EPO-CAN 20 and Amgen
20010103 trials used ESAs in cancer patients not on
active chemotherapy treatment. The results of these
four trials have contributed to the generally accepted
recommendations regarding a more modest hemo-
globin target of 120 g/L and a restriction of ESA use
to cancer patients with anemia who are receiving
chemotherapy.
No Survival Disadvantage Despite the contrary evi-
dence, some large randomized controlled trials of ESA
therapy have failed to demonstrate a negative impact
on overall survival. Studies involving patients receiv-
ing chemotherapy for non-small-cell lung cancer
(early versus late intervention) with epoetin alfa 24
and placebo-controlled trials of darbepoetin 25 did not
reveal any survival decrement. Another randomized
double-blind placebo-controlled trial of patients with
TABLE VI U.S. Agency for Healthcare Research and Quality Analy-
sis summary of risk of venous thromboembolic events (VTEs) by
hemoglobin (Hb) level, used to stop dosing with erythropoiesis-
stimulating agents 14
Target stop Hb RR of VTEs 95% CI
<120 g/L Not estimable NA
<130 g/L 0.70 0.29 to 1.67
<140 g/L 1.71 1.23 to 2.40
<150 g/L 1.92 1.22 to 3.02
<160 g/L 1.66 1.08 to 2.54
RR = relative risk; CI = confidence interval.
TABLE IV De-escalation of erythropoiesis-stimulating agents (ESAs)
Epoetin alfa 12 Darbepoetin alfa 13
Three times weekly and Weekly dosing schedule Every-3-weeks dosing schedule
weekly dosing schedules
If Hb increases by >10 g/L in If the rate of Hb increase is >10 g/L in a 2-week If the rate of Hb increase is >15 g/L per
any 2-week period or if period or >15 g/L in a 3-week period, or when 3-week period or when Hb>120 g/L,
Hb>120 g/L, the dose should Hb>120 g/L, the dose should be the dose should be reduced by 40%
be reduced by 25% reduced by 25% of the previous dose
If Hb>130 g/L, the dose If Hb>130 g/L, dosing should be temporarily If Hb>130 g/L, dosing should be
should be temporarily withheld until Hb falls to 120 g/L; at that time, temporarily withheld; once Hb falls to
withheld until Hb<120 g/L therapy should be reinitiated at a dose 25% 120 g/L, therapy should be reinitiated at
 and reinitiated at a dose 25% below the previous dose a dose 40% below the previous dose
below the previous dose
Hb = hemoglobin.
TABLE V Dose escalation of erythropoiesis-stimulating agents (ESAs) for inadequate hemoglobin (Hb) response
Epoetin alfa 12 Darbepoetin alfa 13
Three-times-weekly dosing schedule Weekly dosing schedule Weekly dosing schedule Every-3-weeks dosing schedule
If response is unsatisfactory after If response is unsatisfactory If no response is observed after Dose escalation is not
4 weeks of treatment, the dose after 4 weeks of treatment, 6 weeks of therapy, the dose recommended because of an
should be increased to 300 IU/kg the dose should be increased can be increased to absence of additional efficacy
three times weekly for 4 weeks to 60,000 IU weekly 4.5 mg/kg weekly benefit at higher dose levels
for 4 weeks for this schedule 20MIKHAEL et al.
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small-cell lung cancer demonstrated similar survival
rates in epoetin alfa and placebo arms 26.
Recently, another trial (Amgen study 20010145)
designed to explore a potential survival advantage
when patients with extensive-stage small-cell lung
cancer undergoing platinum-plus-etoposide chemo-
therapy were given darbepoetin alfa was completed.
This randomized phase III placebo-controlled study
showed no survival advantage in the darbepoetin arm,
with a median survival in both arms of 40 weeks,
and a hazard ratio (darbepoetin/placebo) of 0.93 (95%
CI: 0.78 to 1.11) 27.
The first Cochrane meta-analysis on this topic
included trials through December 2001 and reported
inconclusive evidence on the potential impact of ESA
therapy on overall survival (HR: 0.81; 95% CI: 0.67 to
0.99) 28. The updated Cochrane meta-analysis, incor-
porating trials up to 2005 (including the BEST, EN-
HANCE, and EPO-CAN 20 studies), again concluded with
uncertainty regarding “whether and how epoetin or
darbepoetin affects overall survival” (HR: 1.08; 95%
CI: 0.99 to 1.18) 6.
Tumour Progression Tumour progression second-
ary to the activation of erythropoietin receptors has
been questioned 29. The BEST and ENHANCE trials both
showed reduced tumour control in the setting of tar-
geting hemoglobin levels higher than current usual
practice. Another study, DAHANCA, was modeled after
the ENHANCE study to address some of the latter study’s
methodologic issues 30.
The DAHANCA Study was a prospective trial in
patients with squamous cell carcinoma of the head
and neck who were undergoing treatment with de-
finitive radiotherapy. Patients were randomized to
darbepoetin or placebo with a primary endpoint of
locoregional control rate at 5 years. An interim analy-
sis of 484 patients demonstrated a 10% increase in
the locoregional failure rate among darbepoetin-
treated patients (p = 0.01). Overall survival was not
significantly different, but appeared to trend towards
shorter survival in the ESA arm (p = 0.08). There were
limitations to this study, including a lack of uniform
imaging assessment at baseline or at recurrence, and
a lack of confirmation of recurrent disease by tissue
biopsy. The final study analysis will be reported to
the U.S. Food and Drug Administration in late 2008.
The relationship between the presence of eryth-
ropoietin receptors and tumour proliferation because
of exogenous erythropoietin with the use of ESAs has
not yet been firmly established. Likewise, the func-
tion of erythropoietin receptors is not well understood.
The in vitro studies to date vary in their findings and
have been called into question based on assessment
methodology 31.
Safety Conclusions Safety issues surrounding ESAs
for the treatment of cancer-related anemia include
thromboembolic risk, survival, and tumour prolifera-
tion. The risk of thromboembolic events are increased
with ESAs, and careful monitoring of hemoglobin lev-
els in patients is mandatory. In May 2004, the U.S.
Food and Drug Administration’s Oncologic Drugs
Advisory Committee (ODAC) revised product label-
ling to include warnings against maintaining hemo-
globin levels above 120 g/L. The negative survival
studies are difficult to interpret in the context of
current practice because of their higher-than-recom-
mended hemoglobin targets, higher-than-recom-
mended doses used, methodologic limitations in the
individual trials, and the enrolment of patients not on
active chemotherapy. The trials evaluating disease
control rates suffer from similar limitations.
Because of the results observed with respect to
overall survival in the Amgen 20010103 Study (dis-
cussed earlier), ODAC met again in May 2007. That
meeting resulted in the initiation of black box warn-
ings in both Canada and the United States 32. The
panel voted to have Amgen and Johnson & Johnson
further strengthen the warning labels of their ESAs and
conduct additional safety studies on these agents. The
final ODAC report is pending.
2.2.4 Iron
Despite the availability and ease of administration of
ESAs to treat CIA in cancer patients, only about 60% of
patients experience an adequate response to such
agents 6. Given that one of the pathologic mechanisms
in anemia of cancer is the sequestration of iron out of
the available circulating pool, and that ample experi-
ence exists in nephrology regarding administration
of parenteral iron to improve hemoglobin levels in
patients with chronic renal failure who are receiving
ESAs, attempts have been made to improve the re-
sponse to ESAs in oncology by supplementing with
iron.
A few studies have tested iron supplementation
in anemic cancer patients receiving chemotherapy and
ESAs. In a study by Auerbach et al. 33, cancer patients
on chemotherapy who were anemic and receiving
weekly epoetin alfa 40,000 IU were randomized to
no iron supplementation, oral iron supplementation,
total dose intravenous infusion of iron dextran, or
weekly intravenous iron dextran. Patients receiving
parenteral iron supplementation experienced a greater
improvement in their hemoglobin level, and more
patients experienced a hemoglobin response (hemo-
globin at least 120 g/L or an increase of at least
20 g/L). Quality-of-life analyses suggested that pa-
tients treated with parenteral iron experienced im-
provements in energy, activity, and overall quality of
life.
In another study by Vandebroek et al. 34, patients
receiving chemotherapy for non-myeloid malignan-
cies and being treated with darbepoetin alfa 500 mg
subcutaneously every 3 weeks were randomized to
oral iron, no iron, or iron sucrose 200 mg intravenously
every 3 weeks. Fewer patients required transfusions
when treated with intravenous iron. Hemoglobin lev-MANAGEMENT OF ANEMIA IN CANCER
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els and clinically meaningful improvements in scores
on the Functional Assessment of Cancer Therapy–
Fatigue appeared higher, but differences were not sta-
tistically significant. Iron supplementation was not
associated with any significant toxicities. This study
is currently available only in abstract form.
In a recently published study by Henry et al. 35,
patients treated with epoetin alfa at a weekly dose of
40,000 IU were randomized to weekly intravenous
sodium ferric gluconate 125 mg, oral ferrous sulphate
325 mg three times daily, or no iron. Hemoglobin
increase was significantly better in the intravenous
group as compared with the oral iron and no iron
groups (24 g/L vs. 16 g/L vs. 15 g/L respectively; p =
0.0092 for intravenous as compared with oral iron).
Hemoglobin response was seen in 73% of intrave-
nous iron-treated patients as compared with 45% of
patients treated with oral iron and 41% receiving no
iron.
In another study by Bellet et al. 36, cancer patients
receiving chemotherapy and ESAs were randomized
to intravenous iron sucrose or to no iron after 8 weeks
of  ESA treatment. All patients continued with ESA
therapy for up to 12 weeks. Regardless of the response
to the initial 8-week course of ESA alone, patients re-
ceiving iron sucrose experienced a greater hemoglo-
bin rise than did patients not receiving iron.
It appears from the published literature that
supplementation with parenteral iron is associated
with benefits in patients treated with ESAs. Hemoglo-
bin level and hemoglobin response both improve, and
the frequency of transfusions declines. Parenteral iron
appears to be well tolerated, particularly the iron su-
crose and sodium ferric gluconate formulations.
Despite the benefits, outstanding questions remain
regarding iron supplementation in patients with CIA
who are receiving ESAs. Most of the studies have initi-
ated iron supplementation along with an ESA, except
for one study that tested iron after 8 weeks of ESA
therapy. No study has compared upfront iron supple-
mentation with no iron supplementation in only poor
ESA responders. The studies screened patients and did
not enrol patients who were felt to be iron-deficient
(defined as a serum ferritin level below 100 ng/L and
a transferrin saturation below 15%). Patients who are
iron-deficient should initially be treated with iron
rather than an ESA. Regarding the potential for induc-
ing a state of iron overload, the two fully published
studies of iron supplementation accepted patients with
ferritin levels of up to 675 pmol/L 33 and 900 ng/mL
(approximately 2025 pmol/L) 35.
All of the available studies had rather limited
periods of follow-up. Potential long-term toxicities
of parenteral iron supplementation in cancer patients
on chemotherapy have not been reported. No com-
parative data have been developed to inform the most
effective schedule or iron formulation for use in CIA
patients on an ESA. Information is also lacking re-
garding the potential value of new oral iron com-
pounds (heme iron polypeptide with folic acid or
polysaccharide iron, vitamin B complex, and folic
acid) in this group of patients.
Despite the limited available evidence, the pro-
vision of parenteral iron to patients with CIA appears
to improve response to the ESA and represents a rea-
sonable treatment option for physicians to consider
for their patients, even for those patients who experi-
ence a poor response to an ESA. Figure 3 summarizes
iron management in patients with CIA.
3. SUMMARY
Anemia is a common finding in cancer patients, most
often as a result of chemotherapy. The management
of anemia requires a comprehensive approach of ap-
propriate diagnosis, exclusion of reversible causes,
and use of ESAs and iron supplementation. The ulti-
mate goal of treating CIA is to increase hemoglobin
levels to reduce the need for transfusions and im-
prove quality of life for the patient. Recommenda-
tions for the use of ESAs include initiation at a
hemoglobin level below 110 g/L, a target hemoglo-
bin of 120 g/L, and dose adjustments to stay within
appropriate levels. Hemoglobin should be regularly
monitored, and rationales for discontinuation of ESAs
or re-initiation should be observed.
Safety issues have recently been raised, namely
thromboembolic risk, impact on survival, and tumour
progression. Although these mechanisms are not
completely understood, strategies to enhance safety
include thrombosis prophylaxis when indicated and
targeting to appropriate hemoglobin levels. Iron me-
tabolism is critical to anemia, and the use of iron
FIGURE 3 Iron assessment and supplementation in chemotherapy-
induced anemia. TSAT = transferrin saturation; BM = bone marrow;
ESA = erythropoietic-stimulating agent; IV = intravenous.MIKHAEL et al.
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supplementation (especially parenteral iron) may
improve response to ESAs, further reducing the need
for transfusions.
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